

06 June 2023

Biological Medicines (MS)

I have a Freedom of information query. How many patients has your trust/health board treated in the past 6 months (for any disease) with the following drugs:

- Aubagio (teriflunomide)
- Avonex (interferon beta-1a)
- Betaferon (interferon beta-1b)
- Brabio (glatiramer acetate)
- Copaxone (glatiramer acetate)
- Extavia (beta interferon-1b)
- Gilenya (fingolimod)
- Lemtrada (alemtuzumab)
- Kesimpta (ofatumumab)
- Mavenclad (cladribine)
- Mayzent (siponimod)
- Ocrevus (ocrelizumab)
- Plegridy (peginterferon beta-1a)
- Ponvory (ponesimod)
- Rebif (beta interferon-1a)
- Tecfidera (dimethyl fumarate)
- Tysabri (natalizumab)
- Tysabri (natalizumab) pre-filled syringes ONLY
- Vumerity (diroximel fumarate)
- Zeposia (ozanimod)

Response

These figures refer to BHSCT resident patients only and those with a diagnosis of MS.

We are unable to provide this information for any other disease as this would not be centrally held.

Aubagio (teriflunomide)	38
• Avonex (interferon beta-1a)	20
• Betaferon (interferon beta-1b)	2
• Brabio (glatiramer acetate)	0

06 June 2023

• Copaxone (glatiramer acetate)	17
• Extavia (beta interferon-1b)	0
• Gilenya (fingolimod)	15
• Lemtrada (alemtuzumab)	0
• Kesimpta (ofatumumab)	2
• Mavenclad (cladribine)	6
• Mayzent (siponimod)	1
• Ocrevus (ocrelizumab)	95
• Plegridy (peginterferon beta-1a)	7
• Ponvory (ponesimod)	0
• Rebif (beta interferon-1a)	13
• Tecfidera (dimethyl fumarate)	106
• Tysabri (natalizumab)	23
• Tysabri (natalizumab) pre-filled syringes ONLY	19
• Vumerity (diroximel fumarate)	0
• Zeposia (ozanimod)	0